EUR 2.85
(-2.9%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 42.4 Million CAD | -5.34% |
2022 | 44.8 Million CAD | 8.17% |
2021 | 41.41 Million CAD | 5.0% |
2020 | 39.44 Million CAD | 69.95% |
2019 | 23.2 Million CAD | 385.16% |
2018 | -8.13 Million CAD | -1920.42% |
2017 | -402.81 Thousand CAD | -102.23% |
2016 | 18.04 Million CAD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | 33.08 Million CAD | -9.66% |
2024 Q1 | 36.62 Million CAD | 4.07% |
2024 Q3 | 31.17 Million CAD | -5.79% |
2023 Q3 | 37.4 Million CAD | -21.76% |
2023 Q1 | 44.7 Million CAD | -0.21% |
2023 Q2 | 47.8 Million CAD | 6.93% |
2023 FY | 42.4 Million CAD | -5.34% |
2023 Q4 | 35.19 Million CAD | -5.91% |
2022 FY | 44.8 Million CAD | 8.17% |
2022 Q4 | 44.8 Million CAD | -0.15% |
2022 Q3 | 44.86 Million CAD | -2.12% |
2022 Q2 | 45.84 Million CAD | -4.67% |
2022 Q1 | 48.08 Million CAD | 16.11% |
2021 Q2 | 25.96 Million CAD | -61.81% |
2021 Q4 | 41.41 Million CAD | 58.64% |
2021 Q3 | 26.1 Million CAD | 0.55% |
2021 FY | 41.41 Million CAD | 5.0% |
2021 Q1 | 67.98 Million CAD | 72.38% |
2020 Q1 | 44.54 Million CAD | 91.95% |
2020 Q4 | 39.44 Million CAD | -5.59% |
2020 Q2 | 42.8 Million CAD | -3.91% |
2020 Q3 | 41.77 Million CAD | -2.4% |
2020 FY | 39.44 Million CAD | 69.95% |
2019 FY | 23.2 Million CAD | 385.16% |
2019 Q4 | 23.2 Million CAD | 9.09% |
2019 Q1 | 3.41 Million CAD | 141.95% |
2019 Q3 | 21.27 Million CAD | 133.66% |
2019 Q2 | 9.1 Million CAD | 166.66% |
2018 FY | -8.13 Million CAD | -1920.42% |
2018 Q4 | -8.13 Million CAD | -380.18% |
2018 Q1 | 1.76 Million CAD | -90.3% |
2018 Q3 | -1.69 Million CAD | 0.0% |
2017 Q4 | 18.19 Million CAD | 0.0% |
2017 FY | -402.81 Thousand CAD | -102.23% |
2016 FY | 18.04 Million CAD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 42.09 Million EUR | -0.74% |
Redcare Pharmacy NV | 191.33 Million EUR | 77.835% |